Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06562907 · ClinicalTrials.gov registry record · Phase 1

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

A Phase 1 study of Weight Management, sponsored by Gilead Sciences.

Recruiting
Registry status
Phase 1
Development phase
134
Enrollment target
3
Study locations

NCT06562907 is a Phase 1 study of Weight Management that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 134 participants, below the 852-participant average among 8 other Weight Management trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06562907, a Phase 1 study of Weight Management, is actively recruiting participants, sponsored by Gilead Sciences.

RECRUITING
Registry status
Phase 1
Development phase
134 participants
Enrollment target
3
Study locations

Study Summary

The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2 Diabetes Mellitus (T2DM). The primary objectives of this study are: * To characterize the pharmacokinetics (PK) of GS-4571 following single and multiple ascending oral doses of GS-4571. * To evaluate the effect of concomitant food intake and (if conducted) a representative acid-reducing agent (proton pump inhibitor (PPI), omeprazole) on the PK of GS-4571. * To evaluate the safety and tolerability of single and multiple ascending oral doses of GS-4571.

Conditions Studied

Weight Management

Interventions

  • DRUG Placebo
  • DRUG Omeprazole
  • DRUG GS-4571

Study Locations (3)

Florida

  • Qps-Mra, Llc. - Miami

Texas

  • ICON Early Phase Services, LLC - San Antonio

Utah

  • ICON - Salt Lake City

Trial Details

FieldValue
Enrollment Target 134 participants
Start Date 2024-08-28
Est. Completion 2026-07
Phase Phase 1

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06562907

The ClinicalTrials.gov registry entry for NCT06562907 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 852-participant average among 8 other Weight Management trials with a reported enrollment target (84% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Weight Management appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06562907 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Texas, Utah.

Frequently Asked Questions

What is clinical trial NCT06562907 about?

NCT06562907 is a clinical study titled "Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)". The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2 Diabetes Mellitus (T2DM). The primary objectives of this study are: * To...

What is the current status of trial NCT06562907?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2024-08-28. Estimated completion is 2026-07.

What conditions does trial NCT06562907 study?

This clinical trial studies the following conditions: Weight Management.

What interventions are being tested in trial NCT06562907?

The interventions under investigation include: Placebo (DRUG), Omeprazole (DRUG), GS-4571 (DRUG).

Who is sponsoring clinical trial NCT06562907?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06562907 being conducted?

This trial has 3 study locations across Florida, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Weight Management

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Weight Management

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.